# Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

> **NCT02415595** · PHASE2 · TERMINATED · sponsor: **ViiV Healthcare** · enrollment: 210 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** BMS-955176
- **DRUG:** EFV
- **DRUG:** TDF/FTC

## Key facts

- **NCT ID:** NCT02415595
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-12
- **Primary completion:** 2016-05-26
- **Final completion:** 2017-08-21
- **Target enrollment:** 210 (ACTUAL)
- **Why stopped:** The trial ended early due to GI intolerability and treatment-emergent resistance.
- **Last updated:** 2018-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02415595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02415595, "Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02415595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*